p l a n t a c o r


  Plantacor, Inc. is a specialty biopharmaceutical company engaged in the development of therapeutic drugs for the treatment of cancer and other human diseases. The Company’s strategy is to fill the developmental gap between basic institutional research and clinical development.  This is accomplished by addressing manufacturing challenges, designing appropriate drug delivery systems, completing preclinical work, filing Investigational New Drug (IND) applications and entering human clinical trials with drug candidates.

The Company’s first product candidates are focused on unique analogs and novel formulations of known tumor growth inhibiting compounds derived from a natural source.  According to the National Cancer Institute, approximately 70% of the currently approved anticancer drugs are either natural compounds, derived therefrom, or mimic natural compounds in one form or another - a proven resource for oncology drugs.  Clearly, starting with recognized effective natural compounds, modifying their chemical structure and formulation for delivery, improving efficacy while maintaining the safety profile of the original compound, is a successful formula for rapid advancement of drug candidates.

Initial Target
Breast cancer is the most common cancer in women and affects one in eight during their lifetime.  Breast cancer kills more women in the United States than any other cancer except lung cancer.  Basal-like breast cancer, characterized in 2005, has some unique characteristics and is the type of breast cancer that BRCA1 mutation (genetic marker) carriers generally develop. It comprises about 15% of all breast cancers and is very aggressive and has a high mortality rate.  It is primarily treated with chemotherapy and is not a candidate for ER-targeted or HER2-targeted therapies.
It is the target of our first drug candidate, CDIM9.

We are completing the preclinical evaluations and preparing the Investigational New Drug (IND) application.